Compare DAO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | IOVA |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 968.6M |
| IPO Year | 2019 | N/A |
| Metric | DAO | IOVA |
|---|---|---|
| Price | $8.84 | $2.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | 135.9K | ★ 9.8M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 155.59 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $798,421,874.00 | $250,425,000.00 |
| Revenue This Year | $5.23 | $60.94 |
| Revenue Next Year | $13.46 | $60.85 |
| P/E Ratio | $53.98 | ★ N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $6.30 | $1.64 |
| 52 Week High | $11.82 | $8.56 |
| Indicator | DAO | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 44.43 |
| Support Level | $8.81 | $2.18 |
| Resistance Level | $9.90 | $2.32 |
| Average True Range (ATR) | 0.44 | 0.11 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 4.00 | 7.36 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.